Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota. As of April 27, 2023, Cardiovascular Systems, Inc. operates as subsidiary of Abbott Laboratories (NYSE:ABT).
Research context
CARDIOVASC SYS - Frankfurt Stock Exchang appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
CARDIOVASC SYS - Frankfurt Stock Exchang is currently in a long term uptrend where the price is trading 8.5% above its 200 day moving average.
From a valuation standpoint, the stock is 51.9% cheaper than other stocks from the Other sector with a price to sales ratio of 6.1.
CARDIOVASC SYS - Frankfurt Stock Exchang's total revenue sank by 6.1% to $64M since the same quarter in the previous year.
Its net income has increased by 98.4% to $-56K since the same quarter in the previous year.
Finally, its free cash flow fell by 73.5% to $835K since the same quarter in the previous year.
Based on the above factors, CARDIOVASC SYS - Frankfurt Stock Exchang gets an overall score of 3/5.